<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Gouy B</submitter><pubmed_abstract>Acute necrotizing encephalopathy 1 (ANE1) is a very rare disorder associated with a dominant heterozygous mutation in the &lt;i>RANBP2&lt;/i> (RAN binding protein 2) gene. ANE1 is frequently triggered by a febrile infection and characterized by serious and irreversible neurological damage. Although only a few hundred cases have been reported, mutations in &lt;i>RANBP2&lt;/i> are only partially penetrant and can occur &lt;i>de novo&lt;/i>, suggesting that their frequency may be higher in some populations. Genetic diagnosis is a lengthy process, potentially delaying definitive diagnosis. We therefore developed a rapid bedside qPCR-based tool for early diagnosis and screening of ANE1 mutations. Primers were designed to specifically assess &lt;i>RANBP2&lt;/i> and not &lt;i>RGPD&lt;/i> (RANBP2 and GCC2 protein domains) and discriminate between wild-type or mutant &lt;i>RANBP2&lt;/i>. Nasal epithelial cells were obtained from two individuals with known &lt;i>RANBP2&lt;/i> mutations and two healthy control individuals. &lt;i>RANBP2&lt;/i>-specific reverse transcription followed by allele-specific primer qPCR amplification confirmed the specific detection of heterozygously expressed mutant &lt;i>RANBP2&lt;/i> in the ANE1 samples. This study demonstrates that allele-specific qPCR can be used as a rapid and inexpensive diagnostic tool for ANE1 using preexisting equipment at local hospitals. It can also be used to screen non-hospitalized family members and at risk-population to better establish the frequency of non-ANE-associated &lt;i>RANBP2&lt;/i> mutations, as well as possible tissue-dependent expression patterns.&lt;h4>Systematic review registration&lt;/h4>The protocol was registered in the international prospective register of systematic reviews (PROSPERO- CRD42023443257).</pubmed_abstract><journal>Frontiers in neurology</journal><pagination>1282059</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690583</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Rapid and inexpensive bedside diagnosis of RAN binding protein 2-associated acute necrotizing encephalopathy.</pubmed_title><pmcid>PMC10690583</pmcid><pubmed_authors>Desgraupes S</pubmed_authors><pubmed_authors>Gouy B</pubmed_authors><pubmed_authors>Ouyang H</pubmed_authors><pubmed_authors>Nisole S</pubmed_authors><pubmed_authors>Arhel NJ</pubmed_authors><pubmed_authors>Wang YE</pubmed_authors><pubmed_authors>Palazzo AF</pubmed_authors><pubmed_authors>Duan W</pubmed_authors><pubmed_authors>Yeh EA</pubmed_authors><pubmed_authors>Decorsiere A</pubmed_authors><pubmed_authors>Moraes TJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rapid and inexpensive bedside diagnosis of RAN binding protein 2-associated acute necrotizing encephalopathy.</name><description>Acute necrotizing encephalopathy 1 (ANE1) is a very rare disorder associated with a dominant heterozygous mutation in the &lt;i>RANBP2&lt;/i> (RAN binding protein 2) gene. ANE1 is frequently triggered by a febrile infection and characterized by serious and irreversible neurological damage. Although only a few hundred cases have been reported, mutations in &lt;i>RANBP2&lt;/i> are only partially penetrant and can occur &lt;i>de novo&lt;/i>, suggesting that their frequency may be higher in some populations. Genetic diagnosis is a lengthy process, potentially delaying definitive diagnosis. We therefore developed a rapid bedside qPCR-based tool for early diagnosis and screening of ANE1 mutations. Primers were designed to specifically assess &lt;i>RANBP2&lt;/i> and not &lt;i>RGPD&lt;/i> (RANBP2 and GCC2 protein domains) and discriminate between wild-type or mutant &lt;i>RANBP2&lt;/i>. Nasal epithelial cells were obtained from two individuals with known &lt;i>RANBP2&lt;/i> mutations and two healthy control individuals. &lt;i>RANBP2&lt;/i>-specific reverse transcription followed by allele-specific primer qPCR amplification confirmed the specific detection of heterozygously expressed mutant &lt;i>RANBP2&lt;/i> in the ANE1 samples. This study demonstrates that allele-specific qPCR can be used as a rapid and inexpensive diagnostic tool for ANE1 using preexisting equipment at local hospitals. It can also be used to screen non-hospitalized family members and at risk-population to better establish the frequency of non-ANE-associated &lt;i>RANBP2&lt;/i> mutations, as well as possible tissue-dependent expression patterns.&lt;h4>Systematic review registration&lt;/h4>The protocol was registered in the international prospective register of systematic reviews (PROSPERO- CRD42023443257).</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-25T17:33:14.771Z</modification><creation>2025-04-06T04:05:20.953Z</creation></dates><accession>S-EPMC10690583</accession><cross_references><pubmed>38046586</pubmed><doi>10.3389/fneur.2023.1282059</doi></cross_references></HashMap>